GAT229 is primarily used in research settings to study the endocannabinoid system, particularly as a selective agonist for the GPR55 receptor. This receptor is implicated in various physiological processes, including pain modulation, bone density regulation, and cancer cell proliferation. By activating GPR55, GAT229 helps researchers explore its role in these processes and its potential as a therapeutic target. Additionally, it is utilized in neuroscience studies to investigate its effects on neuronal signaling and its potential applications in treating neurological disorders. Its selective action makes it a valuable tool for understanding the complex interactions within the endocannabinoid system.